Regentis Biomaterials Ltd.
IPO Details
Price range
10.00 — 12.00 USD
Shares offered
1.00 M
Deal amount
12.00 M USD
Announcement date
Mar 10, 2025
Offer date
Nov 21, 2025
About Regentis Biomaterials Ltd.
Sector
Industry
CEO
Eli Hazum
Website
Headquarters
Herzliya
Founded
2004
ISIN
IL0012190968
Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.
Related stocks
Frequently Asked Questions
IPO (initial public offering) is the process through which a private company offers its shares to the public for the first time to raise equity capital from a broader base of public investors.
The share price is determined by one or more underwriters, depending on the size of the company. When setting the price, underwriters consider several key factors: the company's current valuation, its future growth potential, associated risks, and how they are compensated, as well as supply and demand and current public market conditions.
An underwriter tries to balance the IPO price — make it high enough to generate sufficient capital for the company, but low enough to attract investors.
Once these factors are evaluated, the company's valuation is divided by the total number of shares, resulting in the price per share.
An underwriter tries to balance the IPO price — make it high enough to generate sufficient capital for the company, but low enough to attract investors.
Once these factors are evaluated, the company's valuation is divided by the total number of shares, resulting in the price per share.
Private companies are owned by a small circle of people: founders, executive management, and private investors. They are closed to public ownership, and their shares can't be bought on exchanges. Conversely, public companies can be owned by members of the public who purchase stocks on the market after the company's IPO.
Regentis Biomaterials Ltd.'s IPO is planned for Nov 21, 2025.
Regentis Biomaterials Ltd. IPO price range is 10.00 - 12.00 USD.
Buying such stocks can be a good idea if the company has strong fundamentals and growth potential. Investors can benefit from the company's performance. Buying an IPO also allows investors to invest in a company at its initial market entry, which gives them a timing advantage before the company reaches its full potential.
However, it's crucial to bear in mind that IPOs, like any other stocks, can be highly volatile. In some instances, companies may be overhyped, leading to an inflated price that could plummet once the initial excitement wanes. Additionally, unlike established companies, IPOs often lack extensive historical data and performance records, making it challenging to fully assess their financial health and business model. This, in turn, can result in potential losses for investors.
The bottom line is that Regentis Biomaterials Ltd. may be a good investment, but you need to do a thorough research before making a decision.
However, it's crucial to bear in mind that IPOs, like any other stocks, can be highly volatile. In some instances, companies may be overhyped, leading to an inflated price that could plummet once the initial excitement wanes. Additionally, unlike established companies, IPOs often lack extensive historical data and performance records, making it challenging to fully assess their financial health and business model. This, in turn, can result in potential losses for investors.
The bottom line is that Regentis Biomaterials Ltd. may be a good investment, but you need to do a thorough research before making a decision.
Companies usually go public to raise capital with the aim of expanding and providing liquidity to early shareholders, and Regentis Biomaterials Ltd. is not an exception here. An IPO provides a company with a significant influx of funds, which can be used for funding new projects, paying down debt, providing returns to early shareholders, and other purposes.
Regentis Biomaterials Ltd. offers 1.00 M shares for sale. This number is defined by the executives and the underwriter depending on how much funds the company hopes to raise and how much of the ownership it's willing to offer.
Regentis Biomaterials Ltd. is going to sell 12.00 M USD worth of shares.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX Regentis Biomaterials Ltd. stocks will be traded under the ticker "RGNT".
Like other stocks, Regentis Biomaterials Ltd. shares will be traded on stock exchanges, e.g., Nasdaq, NYSE, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Regentis Biomaterials Ltd. stocks when the company goes public right from TradingView charts — choose your broker and connect to your account.
Yes, you can track Regentis Biomaterials Ltd. financials in yearly and quarterly reports right on TradingView.